SCHEMBL25935265

SCHEMBL25935265

COc1cc(C(=O)NCC2CC3(CCNCC3)C2)ccc1Nc1ncc2c(n1)N(C(C)C)CC(F)(F)C(=O)N2C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 18/20 0.54
BRD4 O60885 11/20 0.54
BRDT Q58F21 6/20 0.54
MAPK7 Q13164 2/20 0.47
PLK3 Q9H4B4 2/20 0.44
DCLK1 O15075 1/20 0.44
LRRK2 Q5S007 1/20 0.44
PLK2 Q9NYY3 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
PRKCG P05129 1/20 0.44
CLK2 P49760 1/20 0.44
RPS6KA3 P51812 1/20 0.44
NEK4 P51957 1/20 0.44
PTK2 Q05397 1/20 0.44
CAMK2G Q13555 1/20 0.44
CAMK2D Q13557 1/20 0.44
SRPK1 Q96SB4 1/20 0.44
PRKD2 Q9BZL6 1/20 0.44
CSNK1G1 Q9HCP0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30501271 0.91 PLK1 (0.54) PLK1BRD4BRDTMAPK7PLK3
SCHEMBL25031020 0.91 PLK1 (0.62) PLK1BRD4BRDTMAPK7PLK3
SCHEMBL30501283 0.91 PLK1 (0.62) PLK1BRD4BRDTMAPK7PLK3
SCHEMBL25935471 0.88 PLK1 (0.56) PLK1BRD4BRDTMAPK7DCLK1
SCHEMBL30501223 0.88 PLK1 (0.56) PLK1BRD4BRDTMAPK7DCLK1
SCHEMBL25935268 0.88 PLK1 (0.52) PLK1BRD4BRDTMAPK7PLK3
SCHEMBL25031450 0.88 PLK1 (0.52) PLK1BRD4BRDTMAPK7DCLK1
SCHEMBL30501278 0.88 PLK1 (0.52) PLK1BRD4BRDTMAPK7DCLK1
SCHEMBL30135899 0.86 PLK1 (0.50) PLK1BRD4BRDTPLK3PLK2
SCHEMBL30501261 0.86 PLK1 (0.59) PLK1BRD4BRDTMAPK7DCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242541-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242541-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 PLK1 1/4885BRD4 903/4885BRDT 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.